-+ 0.00%
-+ 0.00%
-+ 0.00%

Standard BioTools switches Mass Cytometry sale to Element Biosystems for $5.5 million cash

PUBT·09/30/2026 20:45:03
Standard BioTools switches Mass Cytometry sale to Element Biosystems for $5.5 million cash
  • Standard BioTools replaced its prior Mass Cytometry divestiture deal with a definitive sale agreement to Element Biosystems.
  • Element, an acquisition vehicle formed by GMT Venture Partners, will pay USD 5.5 million in cash at closing, subject to adjustments.
  • The earlier agreement to sell the unit to Multiplex Bio was terminated after GMT Venture submitted an unsolicited proposal on Aug. 29, 2026.
  • The revised terms lift net cash used in Treeline merger exchange-ratio calculations by about USD 15 million versus the Multiplex Bio deal.
  • Closing is targeted by end-2026, substantially concurrent with the planned Treeline transaction, subject to stockholder approval and customary conditions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Standard BioTools Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609301642PRIMZONEFULLFEED9837355) on September 30, 2026, and is solely responsible for the information contained therein.